Rapport Therapeutics (NASDAQ:RAPP – Get Free Report)’s stock price rose 11% on Tuesday . The company traded as high as $22.87 and last traded at $22.72. Approximately 51,085 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 215,976 shares. The stock had previously closed at $20.47.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on RAPP. Jefferies Financial Group started coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price for the company. Stifel Nicolaus began coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective for the company. Finally, TD Cowen assumed coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a “buy” rating on the stock.
Check Out Our Latest Stock Report on RAPP
Rapport Therapeutics Stock Up 9.8 %
Insider Activity at Rapport Therapeutics
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
- Five stocks we like better than Rapport Therapeutics
- What is the S&P 500 and How It is Distinct from Other Indexes
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- 5 discounted opportunities for dividend growth investors
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Why Are Stock Sectors Important to Successful Investing?
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.